Home
Home

ShangPharma

China Biotech In Review: Simcere Receives $503 Million Privatization Offer

China Biotech In Review: Simcere Receives $503 Million Privatization Offer
Seeking Alpha

Age-Related Macular Degeneration: A Promising Investment Opportunity

Age-Related Macular Degeneration: A Promising Investment Opportunity
Seeking Alpha

ShangPharma Surges Most In 10 Months On Acquisition Offer

ShangPharma Surges Most In 10 Months On Acquisition Offer
Bloomberg

ShangPharma rallies15% on buyout offer

ShangPharma rallies 15% on buyout offer
Marketwatch

China Biotech Week In Review: Mindray Medical Continues On Acquisition Path

China Biotech Week In Review: Mindray Medical Continues On Acquisition Path
Seeking Alpha

Are WuXi PharmaTech and ShangPharma M&A Targets?

Are WuXi PharmaTech and ShangPharma M&A Targets?
Seeking Alpha

20 Biotech Stocks That Hedge Funds Are Selling

20 Biotech Stocks That Hedge Funds Are Selling
Seeking Alpha

China Biotech Week In Review: BioBay Park Forms Partnership With Roche, Harvard

China Biotech Week In Review: BioBay Park Forms Partnership With Roche, Harvard
Seeking Alpha

ShangPharma plans $10 M share repurchase program

ShangPharma plans $10 M share repurchase program
Bioscience Technology

ShangPharma Reports 26% Increase in Q1 Revenues

ShangPharma Reports 26% Increase in Q1 Revenues
Seeking Alpha